Next Article in Journal
Eastern Canadian Colorectal Cancer Consensus Conference 2013: Emerging Therapies in the Treatment of Pancreatic, Rectal, and Colorectal Cancers
Previous Article in Journal
Targeting Leukemia Stem Cells: Which Pathways Drive Self-Renewal Activity in T-Cell Acute Lymphoblastic Leukemia?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 1
10.3747/co.23.2810
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Canadian Perspective on the Use of Immunoglobulin Therapy to Reduce Infectious Complications in Chronic Lymphocytic Leukemia

by
S. Lachance
1,*,
A.L. Christofides
2,
J.K. Lee
3,
L.H. Sehn
4,
B.C. Ritchie
5,
C. Shustik
6,
D.A. Stewart
7,
C.L. Toze
8,
E. Haddad
9 and
D.C. Vinh
6,*
1
Université de Montréal, Montreal, QC, Canada
2
New Evidence, Toronto, ON, Canada
3
Canadian Society of Allergy and Clinical Immunology, Toronto, ON, Canada
4
BC Cancer Agency, Vancouver, BC, Canada
5
‖University of Alberta, Edmonton, AB, Canada
6
McGill University Health Centre, Montreal, QC, Canada
7
Tom Baker Cancer Centre, Calgary, AB, Canada
8
Leukemia/Bone Marrow Transplant Program of BC, Vancouver General Hospital, BC Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
9
CHU Sainte-Justine, Departments of Pediatrics and of Microbiology, Immunology, and Infectiology, Université de Montréal, Montreal, QC, Canada
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(1), 42-51; https://doi.org/10.3747/co.23.2810
Submission received: 3 November 2015 / Revised: 3 December 2015 / Accepted: 5 January 2016 / Published: 1 February 2016

Abstract

Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), who typically have increased susceptibility because of hypogammaglobulinemia (HGG) related to their disease and its treatment. Immunoglobulin replacement therapy (IGRT) has been shown to reduce the frequency of bacterial infections and associated hospitalizations in patients with HGG or a history of infection, or both. However, use of IGRT in CLL is contentious. Studies examining such treatment were conducted largely before the use of newer chemoimmunotherapies, which can extend lifespan, but do not correct the HGG inherent to the disease. Thus, the utility of IGRT has to be re-evaluated in the current setting. Here, we discuss the evidence for the use of IGRT in CLL and provide a practical approach to its use in the prevention and management of infections.
Keywords: Chronic lymphocytic leukemia; hypogammaglobulinemia; immunoglobulins; immunoglobulin replacement therapy; infection; ivig; scig; immunodeficiency Chronic lymphocytic leukemia; hypogammaglobulinemia; immunoglobulins; immunoglobulin replacement therapy; infection; ivig; scig; immunodeficiency

Share and Cite

MDPI and ACS Style

Lachance, S.; Christofides, A.L.; Lee, J.K.; Sehn, L.H.; Ritchie, B.C.; Shustik, C.; Stewart, D.A.; Toze, C.L.; Haddad, E.; Vinh, D.C. A Canadian Perspective on the Use of Immunoglobulin Therapy to Reduce Infectious Complications in Chronic Lymphocytic Leukemia. Curr. Oncol. 2016, 23, 42-51. https://doi.org/10.3747/co.23.2810

AMA Style

Lachance S, Christofides AL, Lee JK, Sehn LH, Ritchie BC, Shustik C, Stewart DA, Toze CL, Haddad E, Vinh DC. A Canadian Perspective on the Use of Immunoglobulin Therapy to Reduce Infectious Complications in Chronic Lymphocytic Leukemia. Current Oncology. 2016; 23(1):42-51. https://doi.org/10.3747/co.23.2810

Chicago/Turabian Style

Lachance, S., A.L. Christofides, J.K. Lee, L.H. Sehn, B.C. Ritchie, C. Shustik, D.A. Stewart, C.L. Toze, E. Haddad, and D.C. Vinh. 2016. "A Canadian Perspective on the Use of Immunoglobulin Therapy to Reduce Infectious Complications in Chronic Lymphocytic Leukemia" Current Oncology 23, no. 1: 42-51. https://doi.org/10.3747/co.23.2810

APA Style

Lachance, S., Christofides, A. L., Lee, J. K., Sehn, L. H., Ritchie, B. C., Shustik, C., Stewart, D. A., Toze, C. L., Haddad, E., & Vinh, D. C. (2016). A Canadian Perspective on the Use of Immunoglobulin Therapy to Reduce Infectious Complications in Chronic Lymphocytic Leukemia. Current Oncology, 23(1), 42-51. https://doi.org/10.3747/co.23.2810

Article Metrics

Back to TopTop